As of June 19, 2025, Hexo Corp (HEXO.TO) reports a ROE (Return on Equity) of -340.33%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Hexo Corp's ROE (Return on Equity)
Over recent years, Hexo Corp's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-07-31 | -340.33% |
| 2021-07-31 | -15.70% |
| 2020-07-31 | -98.77% |
| 2019-07-31 | -8.84% |
| 2018-07-31 | -7.23% |
This slight upward trend highlights how Hexo Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing Hexo Corp's ROE (Return on Equity) to Peers
To better understand Hexo Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Hexo Corp (HEXO.TO) | -340.33% |
| Verrica Pharmaceuticals Inc (VRCA) | 776.66% |
| OptiNose Inc (OPTN) | 53.37% |
| BioDelivery Sciences International Inc (BDSI) | 45.18% |
| SIGA Technologies Inc (SIGA) | 27.44% |
| Lotus Pharmaceuticals Inc (LTUS) | 16.20% |
Compared to its competitors, Hexo Corp's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.